Organ and tissue preservation formulations with improved stability shelf life are provided by separating the formulation into a first solution having a pH of at least 7 and a second solution having a pH of less than 7. The first solution includes components with improved stability when stored at a pH of 7 or above , and the second solution includes components with improved stability when stored at a pH below 7. The first solution includes water, a balanced salt solution , a sugar , adenosine , orotic acid , malic acid , L- carnitine, and insulin. The second solution includes water , an antioxidant such as ascorbic acid , a cellular reducing agent such as reduced glutathione , L -citrulline ,creatine monohydrate, L -carnosine , and L- arginine. During use , the first and second solutions are mixed to form a final formulation that can be used at a physiological pH to preserve the function of the tissue or organ.
